143 related articles for article (PubMed ID: 26193987)
1. Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial.
Simon N; Romano O; Michel P; Pinçon C; Vasseur M; Lemahieu N; Barthélémy C; Hebbar M; Décaudin B; Odou P
Cancer Chemother Pharmacol; 2015 Oct; 76(4):865-71. PubMed ID: 26193987
[TBL] [Abstract][Full Text] [Related]
2. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
[TBL] [Abstract][Full Text] [Related]
3. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
[TBL] [Abstract][Full Text] [Related]
4. A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours.
Venugopal B; Awada A; Evans TR; Dueland S; Hendlisz A; Rasch W; Hernes K; Hagen S; Aamdal S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):785-92. PubMed ID: 26289594
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
[TBL] [Abstract][Full Text] [Related]
6. Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose.
Van Nuland M; Rosing H; Thijssen B; Burgers JA; Huitema ADR; Marchetti S; Schellens JHM; Beijnen JH
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):929-937. PubMed ID: 31970932
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.
Freise KJ; Martín-Jiménez T
J Vet Pharmacol Ther; 2006 Apr; 29(2):147-52. PubMed ID: 16515669
[TBL] [Abstract][Full Text] [Related]
8. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy.
Pestieau SR; Schnake KJ; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2001 Mar; 47(3):269-76. PubMed ID: 11320672
[TBL] [Abstract][Full Text] [Related]
9. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J
J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
Kiani A; Köhne CH; Franz T; Passauer J; Haufe T; Gross P; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2003 Mar; 51(3):266-70. PubMed ID: 12655447
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion.
van Riel JM; Peters GJ; Mammatas LH; Honeywell RJ; Laan AC; Ruyter R; van den Berg FG; Giaccone G; van Groeningen CJ
Eur J Cancer; 2009 Sep; 45(14):2519-27. PubMed ID: 19556122
[TBL] [Abstract][Full Text] [Related]
15. No evidence of gemcitabine accumulation during weekly administration.
de Lange SM; van der Born K; Kroep JR; Jensen HA; Pfeiffer P; Cleverly A; van Groeningen CJ; Peters GJ
Eur J Clin Pharmacol; 2005 Dec; 61(11):843-9. PubMed ID: 16283278
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
[TBL] [Abstract][Full Text] [Related]
18. Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
Schmid P; Schweigert M; Beinert T; Flath B; Sezer O; Possinger K
Invest New Drugs; 2005 Mar; 23(2):139-46. PubMed ID: 15744590
[TBL] [Abstract][Full Text] [Related]
19. The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Dumez H; Louwerens M; Pawinsky A; Planting AS; de Jonge MJ; Van Oosterom AT; Highley M; Guetens G; Mantel M; de Boeck G; de Bruijn E; Verweij J
Anticancer Drugs; 2002 Jul; 13(6):583-93. PubMed ID: 12172503
[TBL] [Abstract][Full Text] [Related]
20. Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation.
Grimison P; Galettis P; Manners S; Jelinek M; Metharom E; de Souza PL; Liauw W; Links MJ
J Clin Oncol; 2007 Dec; 25(36):5704-9. PubMed ID: 18089865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
